TCMs in Clinical Trials
An increasing number of TCM formulations are currently being tested in clinical trials and reported on www.ClinicalTrials.gov,45 a service of the US National Institutes of Health. www.ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. As of April 2016, there were >600 clinical
Figure 11.4 Diagram of proposed bakuchiol and ibandronate sodium in relation to the mevalonate pathway. Ibandronate sodium is a bisphosphonate drug that inhibits Fpps in the melavonate pathway. From Meteor Nexus, bakuchiol can first undergo allylic hydroxylation and oxidation to yield a trisubstituted alkene metabolite. CYp2C19 and epoxide hydrolase can metabolize it to yield a mevalonic acid-like metabolite. This metabolite can then possibly act as a competitive inhibitor of mevalonic acid and stimulate the mevalonate pathway.
trials reported using different TCM formulations alone or in combination with Western therapeutics, involving >700 conditions.